SG11202010939WA - Anti-human tlr7 antibody - Google Patents

Anti-human tlr7 antibody

Info

Publication number
SG11202010939WA
SG11202010939WA SG11202010939WA SG11202010939WA SG11202010939WA SG 11202010939W A SG11202010939W A SG 11202010939WA SG 11202010939W A SG11202010939W A SG 11202010939WA SG 11202010939W A SG11202010939W A SG 11202010939WA SG 11202010939W A SG11202010939W A SG 11202010939WA
Authority
SG
Singapore
Prior art keywords
human tlr7
tlr7 antibody
antibody
human
tlr7
Prior art date
Application number
SG11202010939WA
Inventor
Kensuke Miyake
Yusuke Murakami
Yuji Motoi
Atsuo Kanno
Toshiyuki Shimizu
Umeharu Ohto
Takaichi Shimozato
Atsushi Manno
Takashi Kagari
Jun Ishiguro
Kensuke Nakamura
Takashi Isobe
Original Assignee
Daiichi Sankyo Co Ltd
Univ Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd, Univ Tokyo filed Critical Daiichi Sankyo Co Ltd
Publication of SG11202010939WA publication Critical patent/SG11202010939WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202010939WA 2018-05-31 2019-05-30 Anti-human tlr7 antibody SG11202010939WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018104676 2018-05-31
PCT/JP2019/021466 WO2019230869A1 (en) 2018-05-31 2019-05-30 Anti-human tlr7 antibody

Publications (1)

Publication Number Publication Date
SG11202010939WA true SG11202010939WA (en) 2020-12-30

Family

ID=68697552

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010939WA SG11202010939WA (en) 2018-05-31 2019-05-30 Anti-human tlr7 antibody

Country Status (15)

Country Link
US (3) US11091560B2 (en)
EP (1) EP3805389A4 (en)
JP (3) JP6790307B2 (en)
KR (1) KR20210018192A (en)
CN (1) CN112204143B (en)
AU (1) AU2019279206A1 (en)
BR (1) BR112020021266A2 (en)
CA (1) CA3099900A1 (en)
CO (1) CO2020015124A2 (en)
IL (1) IL278962A (en)
MX (1) MX2020011814A (en)
PH (1) PH12020551985A1 (en)
SG (1) SG11202010939WA (en)
WO (1) WO2019230869A1 (en)
ZA (1) ZA202006903B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202010939WA (en) * 2018-05-31 2020-12-30 Daiichi Sankyo Co Ltd Anti-human tlr7 antibody
WO2021146383A1 (en) * 2020-01-17 2021-07-22 BioLegend, Inc. Anti-tlr7 agents and compositions and methods for making and using the same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US20030032090A1 (en) 1997-05-07 2003-02-13 Schering Corporation, A New Jersey Corporation Human receptor proteins; related reagents and methods
DK2180007T4 (en) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosylation technique for antibodies to enhance antibody-dependent cell cytotoxicity
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
MXPA02011618A (en) * 2000-05-25 2003-03-10 Schering Corp Human receptor proteins; related reagents and methods.
MXPA03002974A (en) 2000-10-06 2004-05-05 Kyowa Hakko Kogyo Kk Cells producing antibody compositions.
CA2492671C (en) 2002-03-22 2012-04-17 Aprogen, Inc. Humanized antibody and process for preparing same
DE602004002275T2 (en) 2003-01-07 2007-09-06 Symphogen A/S PROCESS FOR PRODUCING RECOMBINANT POLYCLONAL PROTEINS
WO2007133855A2 (en) 2006-03-27 2007-11-22 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
NZ583397A (en) 2007-10-11 2012-03-30 Daiichi Sankyo Co Ltd ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15
US20140037645A1 (en) * 2008-11-07 2014-02-06 National Jewish Health Diagonsis and treatment of autoimmune diseases by targeting autoimmune-related b cells ("abcs")
CA2750836C (en) 2009-04-09 2018-05-01 Daiichi Sankyo Company, Limited Anti-siglec-15 antibody
WO2011031520A1 (en) * 2009-08-27 2011-03-17 Idera Pharmaceuticals, Inc. Composition for inhibiting gene expression and uses thereof
WO2011159328A1 (en) * 2010-06-16 2011-12-22 Dynavax Technologies Corporation Methods of treatment using tlr7 and/or tlr9 inhibitors
BR112014019825B1 (en) 2012-02-10 2021-08-24 University Of Maryland, Baltimore CHEMIOENZYMATIC GLYCOENGINEERING OF ANTIBODIES AND FC FRAGMENTS OF THE SAME
EP2990419B1 (en) * 2013-04-22 2019-09-18 The University of Tokyo Preventive or therapeutic agent for inflammatory disease
US20160361360A1 (en) * 2015-06-12 2016-12-15 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
CN107735104B (en) * 2015-06-25 2022-05-03 免疫医疗公司 Combination of anti-HLA-DR antibodies or anti-TROP-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors leads to a significant improvement of cancer treatment outcome
EP3316885B1 (en) * 2015-07-01 2021-06-23 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
SG11202010939WA (en) * 2018-05-31 2020-12-30 Daiichi Sankyo Co Ltd Anti-human tlr7 antibody

Also Published As

Publication number Publication date
CN112204143A (en) 2021-01-08
CA3099900A1 (en) 2019-12-05
EP3805389A4 (en) 2022-03-23
JP2021035378A (en) 2021-03-04
US20210332149A1 (en) 2021-10-28
US20210040225A1 (en) 2021-02-11
JP6790307B2 (en) 2020-11-25
AU2019279206A2 (en) 2021-01-14
AU2019279206A1 (en) 2020-12-03
JP7377185B2 (en) 2023-11-09
ZA202006903B (en) 2022-03-30
CO2020015124A2 (en) 2020-12-21
US11578138B2 (en) 2023-02-14
MX2020011814A (en) 2020-12-07
CN112204143B (en) 2024-03-08
TW202000704A (en) 2020-01-01
EP3805389A1 (en) 2021-04-14
IL278962A (en) 2021-01-31
JPWO2019230869A1 (en) 2021-02-12
WO2019230869A1 (en) 2019-12-05
KR20210018192A (en) 2021-02-17
JP2024012394A (en) 2024-01-30
US11091560B2 (en) 2021-08-17
PH12020551985A1 (en) 2021-08-02
BR112020021266A2 (en) 2021-01-26
US20230212306A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
IL279321A (en) Anti-sirpα antibody
SG11202106214YA (en) Novel anti-ccr8 antibody
IL280780A (en) Anti-tigit antibodies
IL279352A (en) Il-11ra antibodies
IL280013A (en) Anti-il36r antibodies
IL283812A (en) Humanized anti-human-pd-1 antibody
IL278010A (en) Galectin-10 antibodies
IL277030A (en) Antibodies
IL282756A (en) Humanized anti-sirpα antibodies
SG11202106171WA (en) Anti-btla antibodies
ZA202101177B (en) Anti-btla antibody
GB201811368D0 (en) Antibody
IL281594A (en) Anti-klrg1 antibodies
ZA202108836B (en) Anti-epha4 antibody
GB201817172D0 (en) Antibody
IL278962A (en) Anti-human tlr7 antibody
GB201806084D0 (en) Antibodies
GB201820006D0 (en) Humanised anti-IL17BR antibody
GB201919062D0 (en) Antibody
GB201912008D0 (en) Antibody
SG11201913540VA (en) Anti-Podoplanin Antibody
GB201900983D0 (en) Antibody
GB201900724D0 (en) Antibody
GB201813597D0 (en) Antibody
GB201809945D0 (en) Antibody